Drugs / UV-4B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02696291 | May 2016 → Mar 2017 | viral infectious disease | Emergent BioSolutions | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-02-01 | Emergent BioSolutions | Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue emergentbiosolutions.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UV-4B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02696291 ↗ |
| Route | Oral | “UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days” NCT02696291 ↗ |